Ernest Lim's investing blog

Unique insights into SGX small caps

tail

Raffles Medical – Potential trading play as its results are just around the corner (20 Feb 23)

el15

Dear all, Raffles Medical caught my attention recently as CLSA raised its target price from $1.70 to $1.92 on 8 Feb 23. $1.92 is a street high target with most analysts’ target price ranging between $1.58 – 1.65. Raffles Medical closed down 1 cent to $1.45 last Fri. Based on my personal view and observation, generally speaking, analysts seldom issue updated call so near to the company’s results release date. I mean there is usually no such urgency to do so, unless they have a significant change in view on the company. For those analysts who do, their calls are […]

Keppel Corp slumps 7% post results to $7.11 – Any trading opportunity ahead? (8 Feb 23)

el15

Dear all, Kep Corp has fallen $0.54 or 7% from $7.65 on 2 Feb to close $7.11 yesterday. In this write-up, I will elaborate on my take on what has happened and whether there is any trading opportunity.   Why did Kep Corp plummet 7%? Kep Corp announced 4QFY22 results on 2 Feb after market. Based on CGS-CIMB report, Kep Corp’s FY22 net profit of S$927m slightly beat estimates, at 102% consensus estimates. So what has caused the sharp drop in share price post results? My guess is that Kep Corp probably drops because a) Kep Corp has appreciated 7.6% […]

Tianjin Pharma – A potential undervalued company, net cash; rides on favourable tailwinds (24 Dec 22)

el15

Dear all Last Friday, personal protection equipment (“PPE”) and glovemakers rallied as much as 3% – 36% in a single day (See Table 1 below). This outperformance may be attributed to concerns that the Covid situation in China may worsen with more infections, or may cause the appearance of new variants, which may spur demand for gloves and personal protection equipment. Table 1: SG glovemakers and PPE share price performance on Friday Source: Ernest’s manual compilations 23 Dec 22 Personally, besides PPE and glovemakers which may benefit, Tianjin Pharmaceutical Da Ren Tang Group (“T14”) may be another potential and perhaps […]